The New England journal of medicine
-
Comment Letter Historical Article
The value of medical spending in the United States.
-
Comment Letter Historical Article
The value of medical spending in the United States.
-
Randomized Controlled Trial Multicenter Study
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. ⋯ After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. (ClinicalTrials.gov number, NCT00006343 [ClinicalTrials.gov].)